tiprankstipranks
Trending News
More News >
SSY Group Limited (HK:2005)
:2005
Advertisement

SSY Group (2005) AI Stock Analysis

Compare
5 Followers

Top Page

HK:2005

SSY Group

(OTC:2005)

Rating:75Outperform
Price Target:
HK$3.50
▲(17.06% Upside)
SSY Group's overall stock score is driven by strong valuation metrics and solid financial performance, despite some cash flow challenges. Technical analysis suggests neutral momentum, with potential bearish signals. The absence of earnings call data and corporate events does not impact the score.

SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)

SSY Group Business Overview & Revenue Model

Company DescriptionSSY Group (2005) is a prominent enterprise engaged in the pharmaceutical industry, primarily focusing on the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company's core offerings include various types of antibiotics, vitamins, and other essential medicines, catering to both domestic and international markets. SSY Group is committed to ensuring the availability of high-quality healthcare solutions to improve patient outcomes.
How the Company Makes MoneySSY Group generates revenue through the sale of its pharmaceutical products. The company's revenue streams are primarily derived from its diverse product portfolio, which includes antibiotics, vitamins, and other critical medicines. SSY Group supplies its products to hospitals, clinics, and pharmacies, as well as engages in export activities to reach international markets. Additionally, strategic partnerships with healthcare providers and distributors enhance its market presence and contribute to its earnings. The company's focus on research and development enables it to innovate and expand its product offerings, driving sustained revenue growth.

SSY Group Financial Statement Overview

Summary
SSY Group demonstrates strong financial performance with robust profitability and balance sheet stability. However, cash flow inconsistencies pose a potential risk that needs addressing.
Income Statement
78
Positive
SSY Group has demonstrated strong profitability with a consistent Gross Profit Margin around 50% and improving Net Profit Margin, reaching 21.9% in 2023. Revenue growth has been steady, though it slightly declined from 2022 to 2023. The EBIT and EBITDA margins have remained healthy, reflecting efficient operations.
Balance Sheet
82
Very Positive
The company maintains a solid financial position with a Debt-to-Equity Ratio around 0.5, indicating moderate leverage. Return on Equity is robust, showcasing effective use of equity to generate profits. The Equity Ratio is strong at over 50%, reflecting stability and financial health.
Cash Flow
65
Positive
SSY Group's cash flow management shows challenges, with fluctuating Free Cash Flow and a declining Free Cash Flow to Net Income ratio. Operating Cash Flow has been positive, but the absence of recent data limits a comprehensive assessment.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.77B6.46B6.43B5.36B4.26B
Gross Profit2.91B3.62B3.44B3.04B2.58B
EBITDA1.74B2.11B1.86B1.40B1.09B
Net Income1.06B1.32B1.12B785.53M611.97M
Balance Sheet
Total Assets12.60B11.97B10.97B10.71B9.25B
Cash, Cash Equivalents and Short-Term Investments1.29B1.62B1.76B1.73B1.51B
Total Debt3.64B3.37B3.21B3.11B2.44B
Total Liabilities5.07B4.70B4.26B4.11B3.24B
Stockholders Equity7.22B6.93B6.21B6.22B5.65B
Cash Flow
Free Cash Flow-49.39M221.88M368.70M359.58M236.61M
Operating Cash Flow491.03M925.75M786.82M747.91M527.64M
Investing Cash Flow-521.76M-640.19M-412.77M-681.23M-287.58M
Financing Cash Flow-295.42M-304.57M-219.30M136.13M318.57M

SSY Group Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.99
Price Trends
50DMA
2.93
Positive
100DMA
2.97
Positive
200DMA
3.16
Negative
Market Momentum
MACD
0.03
Positive
RSI
46.34
Neutral
STOCH
8.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2005, the sentiment is Negative. The current price of 2.99 is below the 20-day moving average (MA) of 3.08, above the 50-day MA of 2.93, and below the 200-day MA of 3.16, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 46.34 is Neutral, neither overbought nor oversold. The STOCH value of 8.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2005.

SSY Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
HK$11.33B11.3123.28%4.41%12.70%9.91%
75
Outperform
$8.85B8.3814.96%5.68%-10.67%-19.27%
74
Outperform
HK$6.24B6.8511.61%6.18%-18.09%-15.08%
73
Outperform
HK$2.04B3.3418.33%5.49%-9.95%67.56%
70
Outperform
HK$10.65B11.448.89%3.81%4.91%-11.80%
60
Neutral
HK$17.66B4.47-4.95%3.59%9.78%-39.36%
49
Neutral
HK$12.88B-4.93%1.52%-0.11%-290.77%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2005
SSY Group
2.99
-0.67
-18.37%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
7.94
2.50
45.96%
HK:2877
China Shineway Pharmaceutical Group Limited
8.17
0.55
7.22%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.36
0.31
29.52%
HK:1681
Consun Pharmaceutical Group Ltd.
13.60
8.45
164.23%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.38
0.86
165.38%

SSY Group Corporate Events

SSY Group’s Drotaverine Hydrochloride Gains Approval in China
Aug 6, 2025

SSY Group Limited has announced that its Drotaverine Hydrochloride, an antispasmodic drug used for treating spasms in the biliary, urinary, and gastrointestinal tracts, has received approval for registration from the National Medical Products Administration of China. This development marks a significant step for the company in expanding its product offerings and strengthening its position in the pharmaceutical market, potentially benefiting shareholders and investors.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for New Drug Production in China
Jul 28, 2025

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Rosuvastatin Calcium and Ezetimibe Tablets (I), a type 4 chemical drug. This approval marks the third such approval for PRC entities, enhancing the company’s position in the pharmaceutical market by expanding its product offerings for treating hypercholesterolemia and hyperlipidemia, potentially benefiting stakeholders through increased market competitiveness.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Expands Pharmaceutical Portfolio with New Drug Approvals
Jul 18, 2025

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new drugs: Ketotifen Fumarate Eye Drops and Calcium Gluconate Injection. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by expanding its portfolio of ophthalmic and treatment drugs.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group’s Cupric Chloride Gains Regulatory Approval in China
Jul 14, 2025

SSY Group Limited has announced that its Cupric Chloride has received approval from the National Medical Products Administration of China for market preparations. This approval marks the third of its kind for PRC entities, indicating a significant step in the company’s product development and potential market expansion, enhancing its position in the pharmaceutical industry.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for New Drug Injections in China
Jul 10, 2025

SSY Group Limited has received approvals from the National Medical Products Administration of China for the production and registration of Potassium Chloride and Sodium Chloride Injection. This development marks the second such approval for PRC entities, enhancing the company’s position in the pharmaceutical market by meeting consistency evaluation standards. The injections are used for treating hypokalemia and heart issues caused by digitalis poisoning, potentially impacting the company’s operations positively by expanding its product offerings.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Advances Innovative Drug Development with Promising Trial Results
Jul 7, 2025

SSY Group Limited has announced significant progress in its innovative drug development projects. The company’s SYN045 tablets, designed to treat pulmonary hypertension, have shown promising results in Phase I clinical trials, with improvements in safety and tolerability. The company plans to advance to Phase IIa trials to further explore efficacy and safety. Additionally, SSY Group is developing new drugs targeting epilepsy and pain treatment, with ongoing compound screening and toxicity assessments. The company is committed to accelerating its drug development efforts and keeping stakeholders informed of its progress.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Exclusive Approval for Children’s Paracetamol Granules in China
Jul 3, 2025

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Paracetamol Granules, a type 3 chemical drug specifically designed for children. This approval grants the company exclusive rights among PRC entities to produce this medication, which is used to treat fever and mild to moderate pain in children, potentially enhancing its market position and offering new opportunities for growth.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for Furosemide Tablet Production
Jun 30, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Furosemide Tablets (20mg), a type 3 chemical drug. This development is significant for the company as it enhances their product portfolio in treating conditions such as edema, hypertension, and acute kidney failure, potentially strengthening their market position and offering new opportunities for growth.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Secures Approval for New Respiratory Drugs
Jun 30, 2025

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two drugs: Diprophylline Injection and Formoterol Fumarate Inhalation Solution. These approvals enhance the company’s portfolio in respiratory treatments, potentially strengthening its market position and offering new options for patients with conditions like asthma and COPD.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Enhances Governance with New Nomination Committee
Jun 20, 2025

SSY Group has established a Nomination Committee to oversee the appointment of directors, ensuring fair and transparent nominations in line with corporate governance standards. The committee, which includes independent non-executive directors, is tasked with reviewing board composition, assessing director independence, and managing succession planning, thereby strengthening the company’s governance framework.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Appoints Ms. Qu Wanrong to Nomination Committee
Jun 20, 2025

SSY Group Limited has announced the appointment of Ms. Qu Wanrong as a member of its Nomination Committee, effective June 20, 2025. Ms. Qu, who has been with the company since 2014 and serves as an executive director and deputy general manager, brings extensive experience in financial audit, public relations, and corporate communications. Her appointment aligns with the company’s compliance with the amended Corporate Governance Code and Listing Rules, enhancing its governance structure and promoting gender diversity within the committee.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Limited Announces Board Composition and Committee Roles
Jun 20, 2025

SSY Group Limited has announced the composition of its board of directors and the roles within its board committees, effective from June 20, 2025. This announcement is significant as it outlines the leadership structure and governance, which could impact the company’s strategic direction and stakeholder confidence.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group’s Caffeine Achieves EU Certification, Boosting Global Market Prospects
Jun 18, 2025

SSY Group Limited has announced that its caffeine product has received the Certificate of Suitability to the European Pharmacopoeia monograph (CEP) from the European Directorate for the Quality of Medicines and HealthCare. This certification is expected to enhance the company’s international sales, brand image, and market share, particularly in European and American markets, by meeting high production and quality standards.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for New Pharmaceutical Products
Jun 12, 2025

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new chemical drugs: Tranexamic Acid and Sodium Chloride Injection, and Levocarnitine Oral Solution. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by addressing bleeding disorders and carnitine deficiency.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Expands Ophthalmic Product Line with New Approval
Jun 9, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Timolol Maleate Eye Drops in unit dose packaging. This marks the company’s first approval of this kind in China and is part of its strategy to expand its ophthalmic product line. The new product is designed to effectively reduce intraocular pressure in various types of glaucoma, enhancing SSY Group’s position in the pharmaceutical market and potentially opening new sales channels by the end of the year.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for New Drug Production
Jun 4, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two chemical drugs: Calcium Gluconate and Sodium Chloride Injection, and Potassium Chloride Granules. These approvals mark a significant step in the company’s product development, enhancing its portfolio in treating conditions such as acute hypocalcemia and hypokalemia, which could strengthen its market position and offer new opportunities for growth.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Reports Decline in Q1 2025 Financial Performance
May 30, 2025

SSY Group Limited announced a significant decline in its unaudited operating results for the first quarter of 2025, with a 36.9% decrease in turnover compared to the same period in 2024. The drop in sales volume of intravenous infusion solutions and ampoule injections contributed to a 50.6% decrease in gross profit and a 59.5% decrease in profit attributable to shareholders. This downturn in financial performance could impact the company’s market positioning and stakeholder confidence.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group’s Dialysis Solution Gains Regulatory Approval
May 28, 2025

SSY Group Limited has announced that its Low Calcium Peritoneal Dialysis Solution has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development marks a significant advancement for the company, enhancing its product offerings in the treatment of renal failure and potentially strengthening its position in the pharmaceutical market.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Gains Approval for New Pharmaceutical Products in China
May 21, 2025

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two drugs: Dronedarone Hydrochloride Tablets and Gabexate Mesylate for Injection. These approvals mark significant advancements in the company’s product offerings, with Dronedarone Hydrochloride targeting atrial fibrillation and Gabexate Mesylate addressing acute pancreatitis. This development enhances SSY Group’s position in the pharmaceutical market, potentially benefiting stakeholders by expanding the company’s portfolio and market reach.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group Limited Successfully Concludes 2025 AGM with Key Resolutions Passed
May 16, 2025

SSY Group Limited held its Annual General Meeting (AGM) in 2025, where all proposed resolutions were passed. Key decisions included the re-election of executive directors, the re-appointment of KPMG as the auditor, and the approval of a final dividend. The meeting also granted the board of directors mandates to issue and repurchase shares, reflecting strong shareholder support and potentially impacting the company’s future financial strategies.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

SSY Group’s Riluzole Gains Approval for Market Use in China
May 15, 2025

SSY Group Limited has announced that its drug Riluzole has received approval from the National Medical Products Administration of China for market use as a bulk drug. This development is significant as Riluzole is used to extend the life of patients with amyotrophic lateral sclerosis (ALS) or delay the need for mechanical ventilation. The approval marks a crucial step in SSY Group’s product development, potentially enhancing its market position and offering new treatment options for ALS patients.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 07, 2025